...
首页> 外文期刊>Transplantation: Official Journal of the Transplantation Society >Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression.
【24h】

Facilitation of tacrolimus-induced heart-allograft acceptability by pretransplant host treatment with granulocyte colony-stimulating factor: interleukin-12-restricted suppression of intragraft monokine mRNA expression.

机译:通过粒细胞集落刺激因子的移植前宿主治疗促进他克莫司诱导的心脏-异体移植的可接受性:白介素12限制了移植物中单因子mRNA表达的抑制。

获取原文
获取原文并翻译 | 示例

摘要

BACKGROUND: Because recombinant human granulocyte colony-stimulating factor (rhG-CSF) is known to modulate function of antigen-presenting cells, we examined effects of pretransplant host treatment with rhG-CSF on allograft survival. METHODS: In DA-to-Lewis rat heart transplantation, hosts were given pretransplant injections of rhG-CSF (250 microg/kg/day subcutaneously from day -5-0) and/or posttransplant injections of tacrolimus (2 mg/kg/day intramuscularly from day 0-3). Cytokine mRNA levels in grafts were measured by real-time reverse-transcription polymerase chain reaction. RESULTS: rhG-CSF pretreatment was effective in prolonging allograft survival only in tacrolimus-treated hosts (P <0.001). Intragraft mRNA expression of interleukin (IL)-12 subunits (p35, p40) at 24 hours after transplantation was significantly (P <0.05) down-regulated by the addition of rhG-CSF and was associated with suppression of interferon-gamma levels on day 6, although other proinflammatory cytokines (tumor necrosis factor -alpha, IL-1beta, IL-6, IL-18) and anti-inflammatory cytokines (IL-10, transforming growth factor-beta) were not. CONCLUSIONS: rhG-CSF pretreatment down-regulates intragraft expression of the type-1 T-helper cell (Th1)-driving cytokine IL-12 and facilitates tacrolimus-induced graft acceptance.
机译:背景:由于重组人粒细胞集落刺激因子(rhG-CSF)可调节抗原呈递细胞的功能,因此我们研究了用rhG-CSF进行移植前宿主治疗对同种异体移植存活的影响。方法:在DA-Lewis大鼠心脏移植中,宿主接受rhG-CSF的移植前注射(从-5-0天起皮下注射250 microg / kg /天)和/或移植后他克莫司注射(2 mg / kg /天)从第0-3天开始肌肉注射。通过实时逆转录聚合酶链反应测量移植物中的细胞因子mRNA水平。结果:仅在他克莫司治疗的宿主中,rhG-CSF预处理可有效延长同种异体移植物的存活(P <0.001)。添加rhG-CSF显着下调了移植后24小时白介素(IL)-12亚基(p35,p40)的移植物中mRNA表达,并与当天干扰素-γ水平的抑制有关如图6所示,尽管其他促炎细胞因子(肿瘤坏死因子-α,IL-1β,IL-6,IL-18)和抗炎细胞因子(IL-10,转化生长因子-β)却没有。结论:rhG-CSF预处理下调了驱动T型辅助细胞(Th1)的细胞因子IL-12的移植内表达,并促进了他克莫司诱导的移植物的接受。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号